CIK 0001601830 · Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464099738
- Phone
- (385) 269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-17 | HERSHBERG ROBERT Director | Grant or award | +88,424 | 162,156 | ||
| 2026-06-17 | Michor Franziska Director | Grant or award | +88,424 | 215,477 | ||
| 2026-06-17 | Sun Elaine D Director | Grant or award | +88,424 | 135,981 | ||
| 2026-06-17 | Dar Zavain Director | Grant or award | +88,424 | 235,655 | ||
| 2026-06-17 | Li Dean Y Director | Grant or award | +88,424 | 1,469,582 | ||
| 2026-06-17 | Bumpus Namandje Director | Grant or award 10b5-1 | +88,424 | 131,595 | ||
| 2026-06-15 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −5,396 | $3.15 | $17K | 1,101,876 |
| 2026-06-05 | Khan Najat CEO and President | Sale 10b5-1 | −23,588 | $3.58 | $84K | 2,175,796 |
| 2026-06-05 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 923,735 | ||
| 2026-06-05 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $3.62 | $145K | 883,735 |
| 2026-06-05 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,263,334 | ||
| 2026-06-03 | Bumpus Namandje Director | Sale 10b5-1 | −4,386 | $3.54 | $16K | 43,171 |
| 2026-06-02 | Borgeson Blake Director | Sale 10b5-1 | −30,000 | $3.68 | $110K | 6,169,863 |
| 2026-05-22 | Gibson Christopher Director | Conversion 10b5-1 | +40,000 | 923,735 | ||
| 2026-05-22 | Gibson Christopher Director | Sale 10b5-1 | −40,000 | $3.08 | $123K | 883,735 |
| 2026-05-22 | Gibson Christopher Director | Conversion · Class B Common Stock 10b5-1 | −40,000 | 4,303,334 | ||
| 2026-05-15 | Khan Najat CEO and President | Shares withheld for taxes | −62,701 | $3.04 | $191K | 2,199,384 |
| 2026-05-15 | Hallett David Chief Scientific Officer | Shares withheld for taxes | −26,657 | $3.04 | $81K | 1,070,494 |
| 2026-05-15 | Gibson Christopher Director | Shares withheld for taxes | −22,821 | $3.04 | $69K | 883,735 |
| 2026-05-15 | Taylor Ben R Chief Financial Officer | Shares withheld for taxes | −25,018 | $3.04 | $76K | 1,107,272 |
Page 2 of 9 · 179 trades